TVEC and Preop Radiation for Sarcoma (4 ml Dose)
Neoadjuvant Intralesional Injection of Talimogene Laherparepvec With Concurrent Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas
Sponsor: Amgen
A PHASE1/PHASE2 clinical study on Soft Tissue Sarcoma, this trial is completed. The trial is conducted by Amgen and has accumulated 14 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jul 2023 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2022 — Jul 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jun 2021 — Jun 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
▶ Show 9 earlier versions
-
Jan 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jul 2020 — Dec 2020 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Apr 2019 — Jul 2020 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Apr 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2018 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2017 — Apr 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2017 — Jun 2017 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Jul 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen
- University of Iowa
For direct contact, visit the study record on ClinicalTrials.gov .